Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Summary

The primary objectives of this study are to characterize \[18F\]molecular neuroimaging (MNI)-1020, a positron emission tomography (PET) radioligand for imaging tau pathology, to visually and quantitatively assess and compare brain uptake and pharmacokinetics of \[18F\]MNI-1020 in participants with probable Alzheimer's disease (AD) and compare with age matched healthy participants, to evaluate the safety of a single injection of \[18F\]MNI-1020 and to compare the distribution of tau (using \[18F\]MNI-1020) and amyloid beta (using florbetapir) in participants with probable AD.

Timeline

Start

2017-09-06

Primary completion

2018-04-30

Completion

2018-04-30

Drugs

Indications